Clinical Comparative efficacy and safety of Unani Drugs

A comparative study of Sharbat toot siyah with laooq sapistan in the management of waram-i-halaq Muzmin (Chronic Pharyngitis)â??

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/04/051674

Enrollment

Registered

2023-04-17

Start date

Unknown

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J312- Chronic pharyngitis

Interventions

Intervention1: Sharbat Toot Siyah (Oral): Sharbate Toot Siyah (25 ml) will be given orally twice a day for 6 week Control Intervention1: Laooq Sapistan(Oral): Laooq Sapistan (7 gm) with luke water wil

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patients of either sex in the age group of 18-60 years 2 Patient with clinically diagnosed with Waram-i-halaq (Chronic Pharyngitis) 3 Patient with raised Absolute eosinophil count and Complete blood count.

Exclusion criteria

Exclusion criteria: Age below 18 and above 60years. 1 Pregnancy and lactation. 2 Those have history of systematic and metabolic disease. 3 Those diagnosed with any other disease of the nose and throat

Design outcomes

Primary

Measure	Time frame
Efficacy will be assessed clinically by improvement in clinical features and following parameter. 1. Improvement of subjective parameters. 2. Reduction in Visual Analogue Scale (VAS) 3. Reduction in Absolute Eosinophil count and CBC Timepoint: 0, 7, 14, 21, 28, 35, 42 days	—

Secondary

Measure	Time frame
Improvement in Clinical Sign and SymptomsTimepoint: 0 and 6th week	—

Countries

India

Contacts

Public ContactDr Usamah Ahmad

State Unani medical College Prayagraj

asifhussainusmani@gmail.com7905831926

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026